The DOI matches its Crossref record.
Patient-Initiated, Twice-Daily Oral Famciclovir for Early Recurrent Genital Herpes: A Randomized, Double-blind Multicenter Trial
Abstract
Objective. —To compare the efficacy and safety of episodic patient-initiated oral famciclovir with placebo in recurrent genital herpes. Design. —Randomized, double-blind, frequent-observation, dose-ranging study comparing twice-daily 125-mg, 250-mg, or 500-mg oral famciclovir with placebo. Patients initiated therapy after self-culturing, reported to the clinic within 12 hours, and were assessed twice daily for at least 5 days. Setting. —Fifteen Canadian university, private practice, or public outpatient clinics. Patients. —A total of 692 patients with culture-proven recurrent genital herpes were randomized; 467 patients experienced a symptomatic episode and commenced treatment. Main Outcome Measure. —Time to complete healing of all lesions. Results. —Famciclovir (all doses) was significantly more effective than placebo in reducing time to healing, time to cessation of viral shedding, and durations of lesion edema, vesicles, ulcers, and crusts. Times to cessation of all symptoms and of moderate to severe lesion tenderness, pain, and burning were also reduced. Patients who initiated famciclovir prior to viral shedding were more likely to not shed virus throughout. All doses were equally effective, safe, and well tolerated. Conclusions. —Oral famciclovir reduced the onset and duration of viral shedding, lesion persistence, and uncomfortable symptoms. Several individual symptoms and lesion stages were also reduced in duration by this episodic therapy. Additionally, our twice-daily observation trial design proved to be a helpful tool for studying recurrent disease. Episodic oral famciclovir provides a convenient and effective alternative for those patients with recurrent genital herpes whose frequency rates do not require continuous antiviral suppression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Fatahzadeh, M., & Schwartz, R. A. (2007) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2007.06.027 · Cited by 570
Seley-Radtke, K. L., & Yates, M. K. (2018) · Antiviral Research · doi:10.1016/j.antiviral.2018.04.004 · Cited by 543
Herpes Simplex Virus Resistance to Acyclovir and Penciclovir after Two Decades of Antiviral Therapy
Bacon, T. H., Levin, M. J., Leary, J. J., Sarisky, R. T., & Sutton, D. (2003) · Clinical Microbiology Reviews · doi:10.1128/cmr.16.1.114-128.2003 · Cited by 504
Antiviral prodrugs – the development of successful prodrug strategies for antiviral chemotherapy
De Clercq, E., & Field, H. J. (2006) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706446 · Cited by 336
Diaz-Mitoma, F. (1998) · JAMA · doi:10.1001/jama.280.10.887 · Cited by 147
Metadata
- Authors
- Sacks, S. L.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 1996-07-03
- Volume
- 276
- Issue
- 1
- Pages
- 44
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W1973082666
- Cited by
- 159
- References
- 0
- FWCI
- 11.67
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Patient-Initiated, Twice-Daily Oral Famciclovir for Early Recurrent Genital Herpes: A Randomized, Double-blind Multicenter Trial. https://app.cochat.ai/papers/10.1001/jama.1996.03540010046029
- The paper
- Sacks, S. L. (1996). Patient-Initiated, Twice-Daily Oral Famciclovir for Early Recurrent Genital Herpes: A Randomized, Double-blind Multicenter Trial. JAMA. https://doi.org/10.1001/jama.1996.03540010046029
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.